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Bianca Ueberberg, Malte Kohns, Ertan Mayatepek and Marc Jacobsen*Abstract
Background: MicroRNAs (miRNAs) are crucial regulators of human immunity e.g. against Mycobacterium
tuberculosis. Against the background of still alarming high mortality of tuberculosis effective biomarkers to improve
diagnosis of M. tuberculosis infection and successful treatment are of major importance.
Conclusions: This review summarizes recent surrogate tissue studies for identification of miRNA biomarker
candidates in human tuberculosis with a special focus on reproducibility and conformance. In addition we provide
assistance for the design of biomarker studies to circumvent major pitfalls.
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impact on study designs
The crucial role of miRNAs in the regulation of immun-
ity e.g. against infections is generally accepted. But do
miRNAs also qualify as biomarkers in this context?
Given the strict prerequisites of biomarkers that should
reliably indicate (or predict) biological conditions [1],
the applicability of miRNAs as biomarkers cannot be
taken for granted. Importantly, the aim to identify bio-
markers has also major implications on the study design.
Especially, definition and characterization of study groups
and samples in human studies are demanding and verifica-
tion of biomarker candidates strongly depends on the
comparability of different studies in this regard. Against
this background, our mini-review aims to (i) summarize
the current state of research on miRNAs as biomarkers in
tuberculosis, (ii) evaluate study designs and comparability
of biomarker studies, and (iii) point out minimal require-
ments and strategies to identify biomarkers.The need for biomarkers in tuberculosis
Mycobacterium tuberculosis (M. tuberculosis), the causative
agent of human tuberculosis, is still a major threat to hu-
mankind. About 8 million new cases and more than 1.3
million deaths annually place tuberculosis among the top* Correspondence: marc.jacobsen@med.uni-duesseldorf.de
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in any medium, provided the original work is pthree fatal infections [2]. However, the vast majority of M.
tuberculosis-infected individuals is capable of controlling
the pathogen. These latently M. tuberculosis-infected
(LTBI) individuals remain infected probably for lifetime.
Diagnosis of tuberculosis and discrimination from LTBI in
children are challenging because of the lack of clinical signs
and imaging findings. Immunological tests (i.e. IFNγ release
assays and tuberculin skin test) do also not discriminate ac-
tive tuberculosis and LTBI. Since treatment regimen differs
depending on the diagnosis, biomarkers for classification
would be of great practical value. Protection against pro-
gression towards active disease is strongly dependent on an
effective immune surveillance. Cellular immunity, especially
CD4+ T cells and macrophages, are crucial players in this
highly orchestrated host-pathogen interaction. The risk of
adult LTBI to develop active tuberculosis is up to 10% per
lifetime (with the majority of progression events occurring
within the first two years; about 5%). Of note, infants and
young children are highly susceptible to tuberculosis with
untreated progression rates of up to 40% within the first
year of infection. Biomarkers that reliably predict disease
progression of LTBI would allow preventive treatment of
highly susceptible individuals as it is done for young chil-
dren. This way, the number of individuals that become in-
fectious could be greatly reduced. As a consequence, also
the number of ‘new’ LTBIs would decrease, a decisive step
for eradication of tuberculosis.
A long treatment regimen about 6 to 9 months is neces-
sary to cure tuberculosis patients. In addition, multidrug-is an open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment courses. Especially insufficient adherence to chemo-
therapy against tuberculosis is a major problem in high
incidence countries leading to treatment failure, develop-
ment of MDR, as well as spread of M. tuberculosis
infections. Shortened treatment e.g. by novel drugs or com-
bination of existing medication would largely improve this
situation and biomarkers that predict successful treatment
could catalyze this process significantly. In childhood tuber-
culosis, prediction of effective treatment is particularly diffi-
cult since detection of M. tuberculosis in sputum fails in the
majority of cases. Reduced pathogen load—defined by spu-
tum conversion in adult tuberculosis patients and a hall-
mark for treatment efficacy—is therefore not definable in
the majority of children. Moreover, bacterial load at treat-
ment onset is expected to be lower in children than in
adults. Biomarkers indicating bacterial load could contrib-
ute to the development of shorter treatment regimens.
Protective immunity against M. tuberculosis is pre-
dominantly based on the T-helper type 1 (TH1) mediated
cellular arm of the host immune response and the fine-
tuned interaction of TH1 cells with M. tuberculosis-
infected macrophages. T-helper cell differentiation and
plasticity was shown to be tightly regulated by miRNAs
[3] and the same holds true for macrophages, the M.
tuberculosis host cell population [4]. Therefore, the rele-
vance of miRNAs for immune regulation in infectious dis-
eases can be taken for granted.
miRNAs in immunity against mycobacterial
infections
The processes underlying the generation and regulation
of miRNAs are reviewed in detail elsewhere [5]. In brief,
miRNAs inhibit mRNA translation leading to mRNA
target degradation and decreased protein expression.
Several miRNA families regulate immune processes.
miR-29, e.g., was shown to inhibit IFNγ expression of T
cells [6]. miR-29 was able to block increased IFNγ levels,
a typical feature of general miRNA knockout mice, and
over-expression of miR-29 increased susceptibility to
tuberculosis [6]. miR-21 was shown to be upregulated in
macrophages after contact with Mycobacterium bovis
BCG [7]. Wu et al. demonstrated miR-21-mediated in-
hibition of interleukin-12 in macrophages and, addition-
ally, found increased apoptosis in dendritic cells due to
miR-21 inhibition of bcl-2 [7]. They conclude that
mycobacteria induce expression of miR-21 leading to
impaired classical macrophage activation and dependent
TH1 immunity. The mechanisms how mycobacteria
interfere with host miRNA expression remain elusive.
miR-155 has been intensively studied with regard to its
role in immunity [8]. Macrophages infected with M. tu-
berculosis show differential miR-155 expression [9,10]
and Kumar et al. identified the M. tuberculosis earlysecreted antigenic factor 6 (ESAT-6) as a crucial factor
in this process [10]. The role of miR-155 in the inter-
action between macrophages and mycobacteria may
have different aspects: interference with mycobacterial
dormancy and inflammatory mediators (i.e. IL-6 and
cyclooxygenase-2) [10]. Recently, Wang et al. demonstrated
that miR-155 is involved in autophagy, an essential process
of mycobacterial killing in host macrophages [11]. Taken
together, previous studies strongly suggest a role of miR-
NAs in host immunity against tuberculosis.
For application as biomarkers of course, miRNA
candidates must be detectable in surrogate tissue and
availability of samples has to be ensured especially in tu-
berculosis endemic countries. Application of surrogate
tissues/cells/body fluids comprises inherent jeopardy (i.e.
differential cellular composition of blood or serum) that
may confound results [1,12]. Hence, single biomarker or
biomarker signatures must be robust enough to define
or predict e.g. disease stages, treatment efficacy, or sus-
ceptibility despite of natural variability. To estimate the
informative values of miRNA as biomarkers, several stud-
ies performed comparative expression analysis mainly in
peripheral blood and sputum samples. These studies com-
prised global approaches to determine multiple miRNAs
or measurement of single miRNA candidates. Results of
these studies are discussed in the next chapters.
miRNAs analyzed in blood and derived cells
during M. tuberculosis infection
Peripheral blood and derived cell populations are fre-
quently used for biomarker discovery and e.g. quantifica-
tion of T-cell subpopulation proportions already made
its way into clinical routine diagnostics of HIV/AIDS. In
tuberculosis, candidate- and array-based global ap-
proaches were applied for miRNA analyses of peripheral
blood and derived cells. An overview of miRNA bio-
marker studies and resulting candidates is provided in
Table 1. The majority of studies focused on comparisons
between patients with active TB, LTBIs, as well as non-
M. tuberculosis-infected (TSTneg) controls. Wang et al.
determined expression profiles of 955 miRNAs (human
and human-viral) of enriched peripheral blood mono-
nuclear cells (PBMCs) from TB patients and contacts
with or without latent M. tuberculosis infection. Classifi-
cation analyses did not discriminate between study
groups but this may be due to small study group sizes
[13]. Of 451 detectable miRNAs, a cluster of 17 miRNAs
showed significant differences between active TB and M.
tuberculosis-infected contacts (Table 1) [13]. Spinelli et al.
used a candidate gene approach to determine expression
of six miRNAs in PBMCs of TB patients and TSTneg in-
dividuals [14]. This study detected miR-424 to be upreg-
ulated in TB patients from both studies whereas no
difference for miR-223 was found [14]. Detailed analyses
Table 1 Biomarker studies of human blood and enriched immune cell populations
Study Study type Study group sizes Upregulated Downregulated Overlap of
differentially
expressed miRNAs
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(not further defined)
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miR-29a miR-142-3p















(Wang et al. 2011)
nv not verified by rtPCR, TB tuberculosis, LTBI latently M. tuberculosis-infected, TSTneg tuberkulin skin test negative individuals, miRNAs microRNAs.
aIndicates a mature miRNA species found at low levels from the opposite arm of a pre-miRNA hairpin.
bWithin the miRNA candidate gene group differentially expressed as compared to TSTneg.
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detected lower expression of miR-223 in PBMCs of TB
patients as compared to LTBI and higher expression as
compared to TSTneg [15]. Comparisons of pulmonary
tissue samples revealed increased miR-223 expression in
the lung of TB patients as compared to healthy controls
[15]. Contrary findings for peripheral blood may there-
fore indicate differential migration activity of miR-223-
expressing cells to affected tissue sites at different
disease stages. Therefore, although miR-223 likely plays
an important role in host immunity against TB, it may
not qualify as a biomarker in surrogate tissue.
miR-144* was mentioned as a candidate regulator or
IFN-γ expression before. Liu et al. performed global
miRNA analysis of PBMCs from TB patients and healthy
controls (three individuals per study group) [16]. This
study identified 30 differentially regulated miRNAs but
decided to focus on increased miR-144 expression in TB
patients [16]. However, contrary findings with regard to
miR-144* expression have been published. Wang et al.
also found increased miR-144* expression in TB patients
(only in comparison to TSTneg) [13] whereas no differ-
ential miR-144 expression was found by others [14].
Since miR-144* was described as an important T-cell
factor in TB, different results may be due to confound-
ing effects of cellular heterogeneity in peripheral blood
[12]. Consequently, we and others performed miRNA
expression analysis in enriched CD4+ T cells [17,18].
Kleinsteuber et al. analyzed miR-144* expression in CD4+ T
cells but since it was not detectable in a subgroup of donors,miR-144* was excluded from further analyses [18]. In
addition, a global miRNA array-based approach detected
decreased miR-144 expression of CD4+ T cells in TB
patients as compared to LTBI but these results of pooled
sample analyses were not verified by quantitative PCR [17].
The same study focused on another promising candidate,
namely miR-29, that was increased in CD4+ T cells from TB
patients (compared to LTBI and TSTneg) [17]. In contrast,
Kleinsteuber et al. detected decreased miR-29a of CD4+ T
cells from TB patients compared to LTBI (but not
TSTneg) [18]. Taken together, as for miR-223, a role
for miR-144 and miR-29 in host immunity against TB is
likely but the applicability of miR-29 as a biomarker has
not been proven.
So far, only one study has been performed determining
miRNA expression profiles of children with TB and LTBI
[18]. Kleinsteuber et al. analyzed differentially expressed
candidates of CD4+ T cells from adult TB patients. This
study confirmed significant downregulation of miR-26a,
miR-29a, and miR-142-3p in peripheral blood of children
with TB compared to children with LTBI. In addition, a
tendency of increased miR-26a, miR-29a, and miR-142-3p
expression after recovery was found [18]. Nevertheless,
the study of Kleinsteuber et al. also demonstrated marked
interindividual differences of miRNA candidate expression
(up to 105-fold). This finding generally questions the
applicability of miRNA as robust biomarkers for discrim-
ination. At least, one would have to apply miRNA expres-
sion pattern of several miRNA, but studies that have
sufficient statistical power are not available.
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ies have been performed to identify miRNAs as surro-
gate tissue biomarkers in peripheral blood but highly
promising candidates have not been identified.
miRNAs detection in serum or plasma during
human M. tuberculosis infection
Various studies identified miRNAs in human plasma
associated with defined structures (i.e. exosomes and
microvesicles apoptotic bodies) that are not degraded by
plasma enzymes. There is arising evidence that circulat-
ing miRNAs exert biological functions e.g. as part of
intercellular communication, and may be used as bio-
markers for human diseases [19]. The appeal of using
plasma miRNAs in clinical applications is high, as separ-
ation and preservation of plasma or serum samples is
clinical routine also in M. tuberculosis endemic coun-
tries. However, variations in preanalytical processing of
samples and lack of established endogenous controls
limit the comparability of results [21].
So far, five studies have been performed to identify
plasma miRNAs that distinguish between patients with
pulmonary TB, LTBI, and TSTneg as well as other infec-
tions or malignant diseases. An overview and compari-
son of the results concerning discrimination between
pulmonary TB and healthy subjects is given in Table 2.
Fu et al. screened pooled serum samples of patients with
pulmonary TB and matched healthy controls for differ-
ential expression of 1,223 miRNAs [20]. They identified
92 differentially expressed miRNAs (59 upregulated
and 33 downregulated in TB patients). Three of theseTable 2 Biomarker studies of human blood serum and plasma







29 TB, 37 healthy contro
(no definition)
Qi et al. 2012 [22] Array for 667 miRNAs
(pooled for study groups)
30 TB, 65 healthy contro
(negative chest X-ray an
IGRA, free from clinical
symptoms of infection)
Miotto et al. 2013 [24] Array for 671 miRNAs
(pools of 10 individuals)
154 pulmonary TB,
105 healthy controls
(negative IGRA or TST,
no risk-factors for LTBI,
no clinically significant
condition) over 2 cohor
Fu et al. 2011 [20] Array for 1,223 miRNAs
(pooled for study groups)
75 TB, 52 healthy contro
(defined as ‘free of
active and latent TB’)






TB tuberculosis, LTBI latently M. tuberculosis-infected, TSTneg tuberkulin skin test neg
aIndicates a mature miRNA species found at low levels from the opposite arm of acandidates were validated by qPCR in individual sam-
ples, but none of these three could be confirmed in later
studies. Two differentially expressed candidates, i.e.
miR-29a and miR-93*, were also assessed in sputum of
the same patients. Notably, increased miR-29a expres-
sion was detected in sputum of TB patients. The same
group investigated miRNA expression patterns of spu-
tum in a second cohort and confirmed differential ex-
pression of miR-29a [21].
Qi et al. compared sera of TB patients to healthy con-
trols and patients with other diseases [22]. Overall, 667
miRNAs were determined in serum pools of TB patients
and healthy controls by microarray analysis. This study
identified 97 differentially expressed miRNAs and se-
lected a set of ten for verification by quantitative PCR. A
set of three miRNAs, i.e. miR-361-5p, miR-889, and
miR-576-3p, was identified that specifically indicated TB
disease. Differential expression of these candidate miR-
NAs was not found by any other study. Abd-el-Fattah
et al. performed microarray-based analysis and validated
results by qPCR to identify miRNAs for discrimination
between pulmonary TB, pneumonia, lung cancer, pleural
transudate, and matched controls [23]. In this study, a
combination of increased miR-182 and miR-197 expres-
sion was found to be specific for TB. Correspondingly,
Qi et al. also detected over-expression of miR-197 in TB
patients [22].
Miotto et al. recruited two patient cohorts: (i) children
with TB, TB/HIV co-infection and controls in Tanzania
and Uganda as well as (ii) adult patients with TB (pulmon-
ary and extra-pulmonary), LTBI, or other pulmonaryUpregulated Downregulated Overlap of
differentially
expressed miRNAs



















ative individuals, miRNAs microRNAs.
pre-miRNA hairpin.
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compared array-based expression patterns of 671 miRNAs
using sample pools of ten patients and 18 sex-matched in-
dividuals from the different subgroups. A cluster of 15
miRNAs distinguished between pulmonary TB and
healthy controls. Within this set of markers, miR-192 was
the only candidate significantly differentially expressed be-
tween the adult and the pediatric study groups. Compar-
ing these results to the study of Qi et al., three miRNAs
(miR-25, miR-590-5p, miR-885-5p) were found concor-
dantly and let-7e disconcordantly regulated. Discrepancies
may be due to different methods e.g. different endogenous
controls used. Qi et al. used miR-16 as endogenous that
has been found to be regulated by others [24].
Zhang et al. applied deep sequencing on serum sam-
ples between groups of patients with TB, pneumonia,
chronic obstructive pulmonary disease, and lung cancer
and healthy controls [25]. They identified a set of 15
differentially expressed miRNAs and a subset of six;
namely, miR-378, miR-483-5p, miR-22, miR-29c, miR-
101, and miR-320b classified the TB patients study
group. miR-483-5p and miR-22 were also regulated con-
cordantly in the study by Fu et al. whereas miR-101 was
not different [20]. No differences for miR-29c were
found in the study by Miotto et al. [24]. In conclusion,
even some overlap of differentially expressed miRNAs
between the studies existed; a common miRNA or miRNA
pattern that classified TB patients was not found. miR-22,Table 3 Key points for the design and evaluation of miRNA b
Topic Major pitfall/mistake(s)
• Cohort definitions • Insufficient inclusion criteria
• Donor/patient characteristics neglected
• Small study group • Insufficient statistical power due to mu
testing in ‘global’ miRNA analyses
• High variability of miRNA candidate
expression due to disease-independen
regulatory mechanisms
• Tissue heterogeneity • Differences in the proportions of miRN
expressing cellular subset confound an
• Statistical design and methods • Application of inappropriate methods
• Significantly different is not the same
as discrimination
• Selection of miRNA targets • Small study groups but extensive array
• ‘Housekeeping’ miRNAs • No comparable internal standardsmiR-25, miR-197, miR-365, miR-483-5p, miR-590-5p, and
miR-885-5p are yet the most promising candidates since
these miRNAs were validated for discrimination of TB
and healthy controls in two studies (see Table 2).
Conclusions of miRNA biomarker studies
Several studies characterized miRNAs of different surro-
gate tissues from M. tuberculosis-infected individuals
and controls but common biomarker candidates have
not been identified so far, neither in serum nor in blood
cells. Several reasons may account for disconcordant
results and possible confounding factors were (i) hetero-
geneous study designs including inconsistent cohort
definitions and small study group sizes, (ii) marked in-
terindividual variability of miRNA candidate expression
especially in whole blood analyses, (iii) missing valid-
ation of targets from global analyses and different house-
keeping miRNAs, (iv) inadequate statistical evaluation
for candidate selection, as well as (v) absence of multi-
factorial classification approaches to define signatures of
candidate miRNA biomarkers in most studies.
As a consequence, future biomarker studies should ad-
here to minimal prerequisites for conformity of study
designs, case/control definitions, analytical settings, and
data evaluation to ensure comparability of results.
Table 3 summarizes some key points that should be con-
sidered for biomarker studies and highlights possible
strategies and approaches to circumvent common pitfalls.iomarker studies
Strategies
• Exact definition of criteria for infection/disease
• Consideration of therapy/concomitant diseases
• Focus on well defined study groups (e.g. children with
tuberculosis/LTBI with a known index case)
ltiple • The definition of study group sizes markedly depends
on (i) the number of miRNA candidates analyzed,
(ii) the variability of target miRNA expression, (iii) the
frequency of miRNA expressing target cells, and (iv) the
desired sensitivity of the approacht
• Include as many of the before mentioned parameters
for study group size calculations
• Cooperate with statisticians
A
alyses
• Usage of purified populations—as homogenous as possible
• Characterization of heterogeneity (e.g. by flow cytometry)
to deconfound results of heterogeneous tissues
• The definition of biomarkers requires discrimination
• Discrimination tests (e.g. support vector machines and
linear discriminance analysis) include training and test
steps and study groups need to be defined accordingly
analyses • Focus on selected miRNAs targets for small study
groups→ hypothesis-driven approach
• Apply a group of ‘housekeeping’ miRNAs used in
previous studies
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ation of biomarker studies will improve comparability of
future studies and may lead to identification of suitable
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